English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Both Thromboxane A2 (TXA2) and F2-isoprostane are thought to be agonists for the Thromboxane A2 receptor (ThR), and the androgenic steroids regulate the expression of ThR. The present study was performed to determine if the ThR plays a role in the hypertension in SHR. Male and female SHR, aged 12 weeks, were treated with a ThR antagonist, SQ29548 (1mg/Kg/d via osmotic mini-pump, or ethanol vehicle) 1 week. Prior to and on treatment days 3 and 6 BP was measured by tail plethysmography. On day 7 rats were anesthetized and mean arterial pressures (MAP) and renal function were measured. By day 6, systolic BP was reduced with the SQ29548 but not ethanol vehicle alone. These data were confirmed by direct measurement; MAP was decreased by 13% in SQ treated male rats compared with controls. In the female rats there was no significant difference. Renal function was not affected by SQ treatment. These data support a role for the ThRr in the hypertension of male SHR. Future studies will be necessary to determine if the receptor agonist is TXA2 or F2 isoprostanes.

Blood pressure (BP) decreases with the thromboxane A2 receptor antagonism in male SHR, but not in female SHR*1